Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	139.04	143.94	87.88	149.1	251.25
Cash & Short-Term Investments	139.04	143.94	87.88	149.1	251.25
Cash Growth	-3.41%	63.79%	-41.06%	-40.66%	-
Prepaid Expenses	1.36	1.09	2.51	3.87	3.83
Restricted Cash	0.45	0.45	-	-	-
Other Current Assets	1.28	4.39	6.03	6.63	2.79
Total Current Assets	142.13	149.87	96.42	159.6	257.88
Property, Plant & Equipment	15.87	20.41	25.91	50.61	0.29
Other Long-Term Assets	2.37	2.46	3.95	3.74	0.72
Total Assets	160.36	172.73	126.28	213.96	258.88
Accounts Payable	3.59	6.37	10.95	21.76	1.99
Accrued Expenses	9.59	9.46	14.04	25.85	4.87
Current Portion of Leases	1.88	1.65	1.52	-	-
Current Unearned Revenue	9.77	18.11	33.56	-	-
Other Current Liabilities	1.4	1.18	2.73	4.14	0.26
Total Current Liabilities	26.23	36.76	62.79	51.75	7.13
Long-Term Debt	43.94	40.51	37.97	37.19	-
Long-Term Leases	17.74	18.95	20.44	25.9	-
Other Long-Term Liabilities	0.93	1.58	4.13	3.74	0.45
Total Liabilities	88.84	97.79	125.33	118.57	7.58
Common Stock	0	0	0	-	-
Additional Paid-In Capital	677.86	587.94	402.39	331.03	312.43
Retained Earnings	-602.31	-513.01	-401.44	-235.65	-61.13
Comprehensive Income & Other	-4.03	-	-	-	-
Shareholders' Equity	71.53	74.94	0.95	95.38	251.3
Total Liabilities & Equity	160.36	172.73	126.28	213.96	258.88
Total Debt	63.56	61.11	59.93	63.09	-
Net Cash (Debt)	75.48	82.83	27.95	86.01	251.25
Net Cash Growth	-8.88%	196.34%	-67.50%	-65.77%	-
Net Cash Per Share	0.30	0.71	0.64	2.28	14.22
Filing Date Shares Outstanding	205	187.02	63.47	38.47	37.76
Total Common Shares Outstanding	204.94	186.96	63.21	38.47	37.76
Working Capital	115.9	113.11	33.63	107.86	250.75
Book Value Per Share	0.35	0.40	0.02	2.48	6.65
Tangible Book Value	71.53	74.94	0.95	95.38	251.3
Tangible Book Value Per Share	0.35	0.40	0.02	2.48	6.65
Machinery	4.7	4.87	4.88	3.04	0.1
Construction In Progress	4.25	6.82	9.63	46	0.2
Leasehold Improvements	2.12	2.12	2.09	2.07	-

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q